Improved Skin Delivery of Voriconazole with a Nanostructured Lipid Carrier-Based Hydrogel Formulation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Song, Seh Hyon | - |
dc.contributor.author | Lee, Kyung Min | - |
dc.contributor.author | Kang, Jong Boo | - |
dc.contributor.author | Lee, Sang Gon | - |
dc.contributor.author | Kang, Myung Joo | - |
dc.contributor.author | Choi, Young Wook | - |
dc.date.available | 2019-03-08T21:38:05Z | - |
dc.date.issued | 2014-08 | - |
dc.identifier.issn | 0009-2363 | - |
dc.identifier.issn | 1347-5223 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/11961 | - |
dc.description.abstract | In order to develop topical preparations of voriconazole (VRC) for the treatment of mycotic infections of the skin, a nanostructured lipid carrier-based hydrogel (NLC-gel) formulation was developed and its physical characteristics, in vitro skin permeation, and retention profiles were examined. A VRC-loaded NLC dispersion, consisting of Precirol ATO 5, Labrafil 1944 CS, and Tween 80, was prepared by high-pressure homogenization and embedded into Carbopol 940 hydrogel. The lipid nanoparticles in the hydrogel were approximately 210 nm in size, with a spherical shape and zeta potential of -30 mV. In a skin permeation study using a Franz diffusion cell mounted with depilated mouse skin, the NLC-gel was superior to conventional cream and microemulsion-based gel formulations, showing 2.8- and 1.7-fold greater flux values, respectively. In addition, the NLC-gel led to markedly greater accumulation of VRC in deeper skin layers as compared with the reference formulations. In conclusion, the novel topical formulation reported here represents an alternative treatment for skin infections such as candidiasis, with less potential for systemic adverse effects than oral therapy. | - |
dc.format.extent | 6 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | PHARMACEUTICAL SOC JAPAN | - |
dc.title | Improved Skin Delivery of Voriconazole with a Nanostructured Lipid Carrier-Based Hydrogel Formulation | - |
dc.type | Article | - |
dc.identifier.doi | 10.1248/cpb.c14-00202 | - |
dc.identifier.bibliographicCitation | CHEMICAL & PHARMACEUTICAL BULLETIN, v.62, no.8, pp 793 - 798 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000339692900008 | - |
dc.identifier.scopusid | 2-s2.0-84906555220 | - |
dc.citation.endPage | 798 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 793 | - |
dc.citation.title | CHEMICAL & PHARMACEUTICAL BULLETIN | - |
dc.citation.volume | 62 | - |
dc.type.docType | Article | - |
dc.publisher.location | 일본 | - |
dc.subject.keywordAuthor | voriconazole | - |
dc.subject.keywordAuthor | nanostructured lipid carrier | - |
dc.subject.keywordAuthor | hydrogel | - |
dc.subject.keywordAuthor | topical delivery | - |
dc.subject.keywordPlus | NANOPARTICLES SLN | - |
dc.subject.keywordPlus | PERCUTANEOUS-ABSORPTION | - |
dc.subject.keywordPlus | TOPICAL DELIVERY | - |
dc.subject.keywordPlus | NLC | - |
dc.subject.keywordPlus | ENCAPSULATION | - |
dc.subject.keywordPlus | PERMEATION | - |
dc.subject.keywordPlus | STABILITY | - |
dc.subject.keywordPlus | DRUGS | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.